Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CYAD-01 (CM-CS1) CAR T-cells in AML, MDS, and Multiple Myeloma
NCT02203825Phase 1Completed
- Sponsor
- Celyad Oncology
- Start
- Mar 2015
- Primary completion
- Mar 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAR-NKG2D in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM), sponsored by Celyad Oncology. Primary endpoint: Safety and feasibility of intravenous administration of CM-CS1 T-cells at 24 months. Started Mar 2015; status: completed.
02
Drugs
CAR-NKG2D
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02203825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02203825.